By 2030, it is anticipated that the Turkey Liver Cancer Therapeutics market will reach a value of $88.7 Mn from $23.4 Mn in 2022, growing at a CAGR of 18.1 % during 2022-2030. Liver Cancer Therapeutics in Turkey is dominated by a few domestic pharmaceutical companies such as Nobel İlaç, Mustafa Nevzat Pharmaceuticals and Deva Holding. The Liver Cancer Therapeutics market in Turkey is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Turkey Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
By 2030, it is anticipated that the Turkey Liver Cancer Therapeutics market will reach a value of $88.7 Mn from $23.4 Mn in 2022, growing at a CAGR of 18.1 % during 2022-2030.
Turkey is an upper middle-income, developing transcontinental country located in Southeastern Europe and Southwestern Asia bordering the Black Sea. Surgery, liver transplantation, chemotherapy, radiation therapy, and targeted therapy are all treatment options for liver cancer in Turkey. Hepatitis B and C infections, alcohol consumption, obesity, and diabetes are all risk factors for liver cancer in Turkey. About 18% of the estimated cancers in Turkey, were liver cancers attributed to alcohol drinking.
The prognosis for liver cancer in Turkey depends on several factors, including the stage of cancer, the patient's overall health, and the treatment received. The five-year survival rate for liver cancer in Turkey is approximately 12%. According to the latest WHO data published in 2020 Liver Cancer Deaths in Turkey reached 4,542 or 1.17% of total deaths. The age-adjusted Death Rate is 5.13 per 100,000 population ranks Turkey 96th in the world. Turkey’s government spent 4.6 % of its GDP on healthcare in 2020.
Market Growth Drivers Analysis
The prevalence of liver cancer in Turkey has risen in recent decades. Liver cancer was the ninth most frequent cancer in Turkey in 2020, according to the Turkish Statistical Institute, with over 4,000 new cases reported. Turkey's workforce is young and well-educated. Furthermore, Turkey benefits from a favourable geopolitical location and a rapid economic rebound following COVID-19, making doing business easier. These aspects could boost Turkey's Liver Cancer Therapeutics market.
Market Restraints
In Turkey, routine screening for liver cancer is not yet widespread. The Turkish Ministry of Health, on the other hand, has developed a screening programme for hepatitis B and C, both of which are substantial risk factors for liver cancer. The manufacturing sector in Turkey is strongly reliant on imports. These factors may deter new entrants into the Turkey Liver Cancer Therapeutics market.
Key Players
The Turkish Medicines and Medical Devices Agency (TITCK) regulates liver cancer therapies in Turkey. TITCK is in charge of drug safety, efficacy, and quality. All medications, including liver cancer therapies, must be approved by the TITCK before they may be marketed or dispensed in the country. In terms of compensation, the Turkish government offers its residents universal health care under the General Health Insurance (GHI) system. For all citizens who are registered with the system, the GHI pays the cost of liver cancer therapies, including liver cancer medicines. The cost of liver cancer therapies is normally covered by the GHI, but patients may incur some out-of-pocket expenses.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Type (Revenue, USD Billion):
By Treatment (Revenue, USD Billion):
By Equipment (Revenue, USD Billion):
By Route of Administration (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.